Isoherranen, N
22  Ergebnisse:
Personensuche X
?
3

Chronic Kidney Disease Alters Vitamin A Homeostasis via Eff..:

Jing, J ; Isoherranen, N ; Robinson‐Cohen, C...
Clinical and Translational Science.  9 (2016)  4 - p. 207-215 , 2016
 
?
4

Interindividual variability of CYP2C19-catalyzed drug metab..:

Shirasaka, Y ; Chaudhry, A S ; McDonald, M...
The Pharmacogenomics Journal.  16 (2015)  4 - p. 375-387 , 2015
 
?
5

Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug In..:

Sager, J E ; Lutz, J D ; Foti, R S...
Clinical Pharmacology & Therapeutics.  95 (2014)  6 - p. 653-662 , 2014
 
?
6

Evidence of CYP3A Allosterism In Vivo: Analysis of Interact..:

Yang, J ; Atkins, W M ; Isoherranen, N..
Clinical Pharmacology & Therapeutics.  91 (2011)  3 - p. 442-449 , 2011
 
?
7

Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and ..:

Peng, C-C ; Templeton, I ; Thummel, K E...
Clinical Pharmacology & Therapeutics.  89 (2011)  6 - p. 888-895 , 2011
 
?
8

Are Circulating Metabolites Important in Drug–Drug Interact..:

Yeung, C K ; Fujioka, Y ; Hachad, H..
Clinical Pharmacology & Therapeutics.  89 (2010)  1 - p. 105-113 , 2010
 
?
9

Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by ..:

Templeton, I ; Peng, C-C ; Thummel, K E...
Clinical Pharmacology & Therapeutics.  88 (2010)  4 - p. 499-505 , 2010
 
?
10

Influence of CYP3A5 Genotype on the Pharmacokinetics and Ph..:

Kharasch, E D ; Walker, A ; Isoherranen, N...
Clinical Pharmacology & Therapeutics.  82 (2007)  4 - p. 410-426 , 2007
 
?
11

Contribution of Itraconazole Metabolites to Inhibition of C..:

Templeton, I E ; Thummel, K E ; Kharasch, E D...
Clinical Pharmacology & Therapeutics.  83 (2007)  1 - p. 77-85 , 2007
 
?
 
?
14

Contributors:

, In: Atkinson's Principles of Clinical Pharmacology,
 
1-15